---
schema_version: "secwatch.filing_event.v1"
accession: "0001730430-26-000031"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2026-07-28T11:33:48+00:00"
generated_at: "2026-07-28T11:35:05.442529+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kiniksa Q2 ARCALYST revenue $243.6M (+55% YoY); raises FY2026 guidance to $980-995M

## Summary
- ARCALYST net product revenue $243.6M in Q2 2026, ~55% YoY growth; ~21% of 14,000 multiple-recurrence patients on therapy.
- 2026 ARCALYST net revenue guidance raised to $980-995M from prior $930-945M.
- Net income $25.4M vs $17.8M in Q2 2025; cash $525.9M, no debt.
- KPL-387 Phase 2 data: median time to treatment response 4.0 days at 300 mg SC monthly; Phase 3 PASTORALE enrolling.
- KPL-1161 preclinical; Phase 1 expected by end of 2026.

## SEC filing metadata
- accession: 0001730430-26-000031
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2026-07-28T11:33:48+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000173043026000031/0001730430-26-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000173043026000031/knsa-20260728x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730430-26-000031
- JSON: https://secwatch.observer/filing/0001730430-26-000031.json
- Plain text: https://secwatch.observer/filing/0001730430-26-000031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.